MedTrace Logo

Dose-Escalation Study of PHA-793887 in Patients With Advanced/Metastatic Solid Tumors

NCT00996255 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2009-10-16

No results posted yet for this study

Summary

The purpose of this open-label, multi center, phase I study, was to determine the safety profile of PHA-793887 administered by intravenous infusion to patients with advanced/metastatic solid tumors. This was a dose-finding study to determine the maximum tolerated dose and the dose of PHA-793887 that can be safely used in phase II investigations.

Conditions

  • Advanced/Metastatic Solid Tumors

Interventions

DRUG

PHA-793887

Escalating doses of PHA-793887 administered weekly by IV infusion for 3 consecutive weeks in 4-week cycles.

Sponsors & Collaborators

  • Nerviano Medical Sciences

    lead INDUSTRY

Principal Investigators

  • Jean-Charles Soria, MD Professor · Institut Gustave-Roussy, Villejuif Cedex, France

  • Chris Twelves, MD Professor · St James University Hospital, Leeds, UK

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-11-30
Primary Completion
2008-02-29
Completion
2008-02-29

Countries

  • France
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00996255 on ClinicalTrials.gov